Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000499080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The use of dupilumab for the treatment of alopecia areata.
Dermatol Online J
October 2024
McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of The Literature.
Dermatol Pract Concept
October 2024
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Introduction: Dupilumab, a monoclonal antibody targeting IL-4 receptor subunit alpha, treats atopic dermatitis (AD) and may impact alopecia areata (AA). AA involves Th1-driven immune activity, and recent studies suggest a role for Th2 pathways. Dupilumab's effects on AA are mixed, with reports of both improvement and worsening.
View Article and Find Full Text PDFInnovation in Alopecia Areata.
Dermatol Clin
January 2025
Department of Dermatology, Yale University School of Medicine, PO Box 208059, New Haven, CT 06520, USA. Electronic address:
Advances in understanding of AA have led to the first approved therapies for this disease, and in the past two years, there have been three medicines approved for the treatment of severe alopecia areata. There are numerous clinical trials of novel therapeutics underway across the spectrum of AA.
View Article and Find Full Text PDFDupilumab-related late adverse events in patients with chronic rhinosinusitis with nasal polyps.
Acta Otolaryngol
October 2024
Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan.
Background: Anti-IL-4 receptor α antibody (dupilumab) has demonstrated favorable sinonasal outcomes for chronic rhinosinusitis with nasal polyps (CRSwNP), which is mainly caused by type 2 inflammation. Although increased blood eosinophil levels and injection site symptoms are frequently observed as acute adverse events (AEs) of dupilumab, limited knowledge is available regarding the late AEs of dupilumab for CRSwNP.
Objectives: We investigated the late AEs following the initiation of dupilumab treatment for CRSwNP.
Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review.
Children (Basel)
July 2024
Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Article Synopsis
- The management of pediatric dermatological conditions has advanced with new biologics and small molecule therapies, originally approved for adults but now being evaluated for children and adolescents.
- The review aims to summarize recently FDA-approved and potential therapies for conditions like alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in pediatric patients.
- Key findings include FDA-approved treatments such as ritlecitinib for alopecia areata and multiple biologics for pediatric psoriasis and atopic dermatitis, with several others undergoing phase 3 clinical trials for potential approval.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!